Last reviewed · How we verify
Bimatoprost Ophthalmic Solution
Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Bimatoprost Ophthalmic Solution |
|---|---|
| Also known as | Lumigan® UD, Lumigan |
| Sponsor | Allergan |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Bimatoprost mimics the action of prostaglandin F by activating F-prostanoid receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the uveoscleral (unconventional) pathway, reducing intraocular pressure. The drug is administered topically as an ophthalmic solution, allowing direct local action in the eye.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia (redness)
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Foreign body sensation
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) (PHASE3)
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) (PHASE3)
- Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (PHASE2, PHASE3)
- Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution (PHASE1, PHASE2)
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes (PHASE1)
- Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bimatoprost Ophthalmic Solution CI brief — competitive landscape report
- Bimatoprost Ophthalmic Solution updates RSS · CI watch RSS
- Allergan portfolio CI